Benefits of Colostrum

Bovine colostrum has been consumed by humans for centuries and has been the subject of increasing scientific interest as a potential source of bioactive compounds. Available evidence from peer-reviewed studies suggests that bovine colostrum may have effects in several areas, including immune modulation, gastrointestinal protection, exercise recovery, and pediatric nutrition [4][5]. However, the strength of evidence varies considerably across these applications, and further research is needed to establish the clinical significance of colostrum supplementation in many contexts.

The bioactive components of bovine colostrum, including immunoglobulins, lactoferrin, growth factors, cytokines, and bioactive peptides, work through multiple mechanisms to influence physiological processes [4]. Immunoglobulins provide passive immune protection by binding to pathogens, lactoferrin exerts antimicrobial effects through iron sequestration and direct membrane disruption, growth factors stimulate cell proliferation and tissue repair, and oligosaccharides serve as prebiotics and decoy receptors for pathogens [3]. The synergistic interaction of these components may contribute to the overall biological activity of colostrum.

This review examines the evidence for the potential health-related properties of bovine colostrum, organized by physiological system and application area. For each area, the review describes the proposed mechanisms, summarizes findings from relevant studies, and notes the limitations of the current evidence base.

A defining feature of colostrum formation is the selective transport of immunoglobulins from maternal circulation into mammary secretions [1]. In bovine species, this process occurs predominantly during the final weeks of pregnancy and the first days postpartum, mediated by specialized receptors on mammary alveolar epithelial cells [1]. The neonatal Fc receptor (FcRn) plays a central role in this transcytosis process, binding IgG at the basolateral membrane of epithelial cells, facilitating transport across the cell, and releasing it into the colostrum at the apical surface [8]. This receptor-mediated transport is highly efficient and selective, enabling the mammary gland to concentrate IgG from maternal blood into colostrum at levels far exceeding those in circulation.

The IgG1 subclass is selectively concentrated in bovine colostrum through this receptor-mediated mechanism, achieving concentrations approximately 7 times higher than those of IgG2 despite similar serum concentrations of both subclasses [8]. This selectivity reflects differences in the amino acid structure of the immunoglobulin heavy chains, which influence binding affinity to FcRn [8]. The pH-dependent nature of FcRn binding (optimal at pH below 6.5 for binding, pH above 6.5 for release) ensures directional transport from blood to milk [8]. The efficiency of this transfer system is remarkable, enabling bovine colostrum to accumulate IgG concentrations of 50 to 150 mg per milliliter, representing the highest immunoglobulin concentration of any natural secretion [1].

The mechanisms of immunoglobulin transfer differ significantly among species [4]. In humans and some other primates, the predominant immunoglobulin in colostrum is secretory IgA, which is locally synthesized by plasma cells in the mammary gland under the influence of the gut-mammary immune axis, rather than being transported from circulation [6]. This fundamental difference in immunoglobulin class and transport mechanism reflects the different placental structures and reproductive strategies of various mammalian species. Understanding these species-specific differences is essential for evaluating the potential of bovine colostrum as a supplement for human consumption.

Bovine colostrum contains various components that may influence immune cell function. Lactoferrin has been shown to modulate the activity of neutrophils, macrophages, and lymphocytes in experimental systems, though the relevance of these findings to human health outcomes requires further study [3]. Lactoferrin performs its cellular functions via lactoferrin receptor interactions, which are located mainly in the microvilli of the intestinal cell membrane. Upon binding to its receptor, lactoferrin can translocate into the cell nucleus, where it triggers gene transcription, resulting in increased cellular proliferation within the intestine [3].

Proline-rich polypeptides (PRP), also known as colostrinin, isolated from ovine colostrum have demonstrated immunomodulatory activity in experimental models, including effects on T-cell maturation and cytokine production [8]. PRP exhibits bidirectional immunomodulatory activity, capable of both stimulating and suppressing immune responses depending on the physiological context. It promotes the differentiation of immature thymocytes into functionally mature T helper cells and modulates the production of interferon-gamma, TNF-alpha, IL-6, and IL-10 [8].

Colostrum also modulates cytokine production in a manner that may promote balanced immune responsiveness. Studies have demonstrated that colostrum can increase the production of anti-inflammatory cytokines (IL-10, TGF-beta) while regulating pro-inflammatory cytokines (IL-6, TNF-alpha) [5]. In a murine model, colostrum supplementation reduced IL-6 production and increased IL-10 production, suggesting an immunomodulatory effect [5]. This cytokine-modulating activity is relevant for conditions characterized by excessive inflammation or immune dysregulation.

Bovine colostrum supplementation has been shown to influence vaccine-induced immune responses in animal studies. In a placebo-controlled trial in dogs, colostrum supplementation resulted in higher IgG titers following canine distemper virus vaccination compared to control animals [9]. The supplemented dogs also exhibited elevated fecal IgA levels and increased fecal microbiota diversity, indicating effects on gut-associated lymphoid tissue function. However, the translation of these findings from animal models to human clinical applications remains uncertain.

The integrity of the intestinal epithelial barrier is essential for preventing the translocation of bacteria and endotoxins from the gut lumen into systemic circulation. Several components of colostrum, including growth factors (EGF, IGF-1, TGF-beta) and lactoferrin, have been shown in experimental systems to influence intestinal epithelial integrity [3][5]. EGF and IGF-1 stimulate proliferation of intestinal epithelial cells, increasing villus height and crypt depth and accelerating mucosal repair after injury. TGF-beta promotes the expression of tight junction proteins (occludin, claudins, ZO-1), reducing paracellular permeability. Lactoferrin enhances barrier function by increasing transepithelial electrical resistance [3].

As reviewed by Yalçıntaş et al. (2024), athletes receiving colostrum supplementation showed attenuated exercise-induced increases in intestinal permeability [2]. This protective effect may be attributed to growth factors that maintain tight junction integrity and immunoglobulins that bind and neutralize luminal endotoxins. In a double-blind, placebo-controlled study, athletes receiving bovine colostrum for 20 days showed decreased intestinal permeability as measured by the lactulose/mannitol ratio, and stool zonulin concentrations were also reduced compared to placebo [10]. These findings suggest that colostrum may help maintain intestinal barrier integrity under conditions of physiological stress.

Non-steroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal damage, including increased intestinal permeability, mucosal ulceration, and bleeding, affecting a substantial proportion of chronic NSAID users. Bovine colostrum has demonstrated protective effects against NSAID-induced gut injury in clinical studies. In a randomized crossover trial, co-administration of colostrum with indomethacin prevented the significant increase in gut permeability observed in the control group [11]. In healthy volunteers, indomethacin caused a 3-fold increase in gut permeability (lactulose/rhamnose ratio) in the control arm, whereas no significant increase was observed when colostrum was co-administered. In patients taking long-term NSAID treatment, initial permeability ratios were low despite continuing on the drug, and permeability was not influenced by co-administration of test solutions [11].

The protective mechanisms involve the growth factors in colostrum (particularly EGF and TGF-beta), which stimulate mucosal repair, and the immunoglobulins, which reduce bacterial translocation across the compromised intestinal barrier [5]. These findings suggest that colostrum may provide a novel approach to the prevention of NSAID-induced gastrointestinal damage, though further research is needed to establish optimal dosing and long-term efficacy.

Bovine colostrum has been investigated as an intervention for infectious diarrhea in children and adults. A systematic review of randomized controlled trials demonstrated that colostrum supplementation was associated with a reduction in the frequency of diarrhea episodes and decreased stool frequency in children [5]. The proposed mechanisms include direct pathogen neutralization by immunoglobulins (particularly effective against rotavirus and enterotoxigenic E. coli), inhibition of bacterial adhesion by oligosaccharides, enhancement of mucosal immunity through sIgA stimulation, and promotion of beneficial microbiota through prebiotic oligosaccharides and lactoferrin-mediated iron sequestration [5].

Studies in both children and adults have reported reduced duration of illness and accelerated recovery from diarrheal episodes with colostrum supplementation. In children with rotavirus-induced diarrhea, those receiving colostrum supplements gained significantly more weight during recovery (approximately 403 g versus 343 g in controls over four days), possibly due to improved nutrient absorption and reduced intestinal damage [5]. A daily colostrum dose providing approximately 200 mg of IgG was reported to be effective in preventing diarrhea in infants in some studies, though optimal dosing has not been established [5].

The anti-inflammatory properties of bovine colostrum components have led to interest in its potential as an adjunctive therapy for inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. The mechanisms include suppression of NF-kappaB activation in intestinal epithelial cells, reduction of pro-inflammatory cytokine production, enhancement of intestinal barrier function, and promotion of mucosal healing [5]. In a study using animal models of colitis, colostrum supplementation reduced intestinal inflammation through modulation of cytokine profiles and enhancement of antioxidant defenses [5]. However, human clinical evidence for IBD management remains limited, and colostrum should not be considered a replacement for standard IBD therapies.

Necrotizing enterocolitis (NEC) is a serious intestinal disease affecting premature infants, with mortality rates of 20 to 30 percent. Bovine colostrum has been investigated as a potential preventive intervention due to its intestinal trophic effects, antimicrobial activity, and immune-modulating properties [3].

Studies in preterm piglets have demonstrated that bovine colostrum is superior to standard formulas in stimulating intestinal function and reducing NEC incidence in animal models. A randomized controlled pilot trial in very low birth weight neonates showed that bovine colostrum supplementation was well-tolerated and associated with trends toward reduced NEC incidence [3]. Colostrum fortification of human milk or donor milk has been shown to increase protein intake and plasma tyrosine levels without adverse effects, while providing antimicrobial activity compared to standard bovine milk-based fortifiers [3].

Important safety considerations exist. Regulatory agencies have cautioned that colostrum products must be free of potential pathogens such as Bacillus cereus, which can be particularly dangerous for immunocompromised premature infants [3]. Further clinical trials are needed before widespread adoption in neonatal intensive care units.

Bovine colostrum supplementation has been investigated for its potential to reduce the incidence of upper respiratory tract infections (URTI). The mechanisms proposed include pathogen neutralization by immunoglobulins in the oropharyngeal and upper respiratory mucosa, enhancement of local immune defenses through sIgA stimulation, and systemic immune modulation through cytokine and growth factor activity [2][5].

A prospective study of 160 children (aged 1 to 6 years) with recurrent URTI and diarrhea demonstrated that four weeks of colostrum supplementation resulted in significant reductions in infection episodes persisting for at least six months [12]. Total infections decreased from a mean of 8.6 to 5.5 episodes, URTI episodes decreased from 5.3 to 3.2, diarrhea episodes decreased from 3.3 to 2.3, and hospital admissions decreased from 2.1 to 0.8. Similar findings were reported in pre-school children, where six weeks of colostrum supplementation was associated with reduced URTI symptom frequency persisting for up to 20 weeks post-supplementation [13].

The sustained benefit beyond the supplementation period suggests that colostrum may induce lasting improvements in immune function rather than providing only temporary passive protection, though larger randomized trials are needed to confirm these findings. Colostrum has also been investigated for its potential role in preventing influenza and other viral respiratory infections, with antiviral mechanisms including direct neutralization of viral particles by immunoglobulins and inhibition of viral attachment by lactoferrin [3].

Several randomized controlled trials have investigated the effects of bovine colostrum supplementation on body composition in conjunction with resistance training. A systematic review summarized that in active men and women, 20 g/day of bovine colostrum for eight weeks, combined with exercise training, was associated with an increase in bone-free lean body mass (mean increase 1.49 kg), while the whey protein control group showed only an increase in total body weight including fat mass [2]. A study in older adults (aged 50 to 75 years) demonstrated that colostrum supplementation during resistance training was associated with improvements in leg press strength compared to whey protein supplementation [2].

The IGF-1 and other growth factors in colostrum may stimulate muscle protein synthesis and satellite cell activation, while the high-quality protein provides essential amino acids for muscle repair and growth [2]. However, the magnitude of effects has been modest in most studies, and the clinical significance for general populations remains to be established.

Studies evaluating colostrum’s effects on exercise performance have reported mixed results. Some studies have found improvements in peak running speed, cycling speed, and buffer capacity in athletes receiving colostrum supplementation [2]. However, other studies have found no significant effect on performance measures, and methodological differences between studies make it difficult to draw definitive conclusions. The proposed mechanisms for any ergogenic effects include improved buffer capacity through buffering proteins, reduced exercise-induced muscle damage through growth factor-mediated repair, enhanced gut barrier function preventing exercise-induced endotoxemia, and maintained immune function during intense training periods [2].

Bovine colostrum has been investigated for its potential to accelerate post-exercise recovery. Growth factors in colostrum (IGF-1, TGF-beta, EGF) may stimulate muscle satellite cell proliferation and differentiation, accelerating repair of exercise-induced microtrauma. Some studies have reported reductions in markers of muscle damage and subjective muscle soreness in athletes receiving colostrum supplementation, though the evidence is not consistent across all studies [2].

Intense exercise increases intestinal permeability (“exercise-induced gut leakiness”), allowing bacterial endotoxins to enter the circulation and trigger systemic inflammation. This phenomenon is exacerbated in hot environments and during prolonged strenuous exercise. Bovine colostrum supplementation has been shown to attenuate this exercise-induced increase in gut permeability in multiple studies.

In a crossover study, 12 males completed two experimental arms involving 14 days of colostrum or placebo supplementation before treadmill running at 70 percent maximal aerobic capacity in hot conditions (30 degrees C, 60 percent relative humidity) [14]. Colostrum supplementation reduced the post-exercise increase in intestinal fatty acid-binding protein (I-FABP), a marker of intestinal cell damage, and reduced circulating bacterial DNA levels compared to placebo. In another study using a double-blind, placebo-controlled, crossover protocol, heavy exercise increased intestinal permeability 2.5-fold in the placebo arm, whereas colostrum truncated the rise by 80 percent [15]. In vitro studies demonstrated that colostrum reduced temperature-induced apoptosis in intestinal cell lines by 60 percent and increased heat shock protein 70 expression [15].

A systematic review of studies assessing the influence of colostrum supplements on gut permeability in athletes concluded that vigorous exercise profoundly increases intestinal permeability, and colostrum supplementation helps to reverse gut permeability in athletes [16]. However, the review noted that well-designed, placebo-controlled, and randomized studies are needed to evaluate long-term safety and efficacy and to determine optimal dose schedules.

Bovine colostrum has emerged as a potential alternative to standard fortifiers for human milk or donor milk feeding in premature infants. The rationale includes superior tolerance compared to formula-based fortifiers, enrichment in immunoglobulins and growth factors that promote intestinal maturation, and lower osmolality which reduces feeding intolerance [3].

A randomized controlled pilot trial demonstrated that bovine colostrum powder combined with human milk and donor milk was well-tolerated by preterm infants, increased protein intake, and improved plasma tyrosine levels without significant adverse effects [3]. Colostrum fortifiers have been shown to increase antimicrobial activity in vitro compared to traditional bovine milk fortifiers. However, bovine colostrum is not a complete substitute for human milk due to differences in protein composition, particularly higher casein content and lower alpha-lactalbumin content relative to human milk [3].

The use of bovine colostrum in preterm infants requires careful consideration of safety issues, including the risk of contamination with pathogenic bacteria. The authors of recent reviews have emphasized that more clinical research is needed before standardized recommendations can be made regarding the use of bovine colostrum in preterm infant nutrition [3].

Bovine colostrum has demonstrated consistent associations with reduced childhood morbidity from infectious diseases in clinical studies [5]. In formula-fed infants, colostrum supplementation for three months resulted in decreased frequency of watery stools, reduced upper respiratory tract infections, shorter duration of diarrhea episodes, and accelerated recovery from illness. No adverse reactions were reported, including in children with milk intolerance [5].

In children with recurrent respiratory tract infections and diarrhea, four weeks of colostrum supplementation resulted in significant reductions in infection episodes persisting for at least six months [12]. The mechanism may involve the enhancement of mucosal immunity through sIgA stimulation and the direct antimicrobial effects of immunoglobulins and lactoferrin.

Bovine colostrum exerts anti-inflammatory effects through multiple mechanisms. Lactoferrin suppresses NF-kappaB activation in intestinal epithelial cells, reducing the production of IL-6, IL-8, TNF-alpha, and other inflammatory mediators [3]. Proline-rich polypeptides inhibit the overproduction of reactive oxygen species and nitric oxide induced by lipopolysaccharide stimulation [8]. TGF-beta in colostrum promotes the development of regulatory T-cells that maintain immune tolerance to food and environmental antigens [3].

Some evidence suggests that components in colostrum may influence allergic sensitization. TGF-beta promotes regulatory T-cell development, which helps prevent inappropriate inflammatory responses. Studies have shown associations between elevated TGF-beta levels in maternal colostrum and reduced risk of atopic dermatitis in infants [3]. The hygiene hypothesis suggests that early immune priming through colostrum components may help prevent allergic diseases by fostering appropriate immune responsiveness.

Milk fat globule-epidermal growth factor 8 (MFG-E8), also known as lactadherin, is a secreted protein found in high concentrations in colostrum that has been identified as a significant anti-inflammatory factor [17]. MFG-E8 mediates the phagocytic clearance of damaged and apoptotic cells from tissues and contributes to the maintenance of intestinal epithelial homeostasis. It has been shown to suppress NF-kappaB-induced transcription of pro-inflammatory cytokines and inhibit neutrophil infiltration of inflamed tissues [17].

In experimental models, MFG-E8 has demonstrated anti-inflammatory effects through multiple mechanisms. It decreases LPS-induced production of pro-inflammatory cytokines from macrophages through suppression of MAPK and NF-kappaB signaling pathways [17]. MFG-E8 also suppresses inflammation in sepsis and ischemia/reperfusion conditions by reducing production of TNF-alpha, IL-1beta, and IL-6 [17]. The administration of recombinant MFG-E8 has been shown to significantly increase survival rates in experimental sepsis models [17]. In addition to its anti-inflammatory properties, MFG-E8 has been identified as a protective factor in inflammatory arthritis, where its deficiency leads to more severe disease burden and increased local and systemic bone loss [18]. The high concentration of MFG-E8 in colostrum suggests it may contribute to the anti-inflammatory and tissue-protective effects observed with colostrum consumption, though direct clinical evidence in humans is limited.

Proline-rich polypeptides (PRP, or colostrinin) isolated from ovine colostrum have been investigated for potential neuroprotective properties. Mechanisms proposed include prevention of amyloid-beta peptide aggregation, modulation of neurite outgrowth, reduction of oxidative stress in neural tissue, and suppression of excessive microglial activation [8].

In a double-blind, placebo-controlled study of Alzheimer’s disease patients, colostrinin administration was associated with improvement in some patients compared to placebo [8]. However, this study was small, and the evidence for cognitive enhancement remains preliminary. Animal studies have shown that PRP improves long-term memory in experimental models. Further research is needed before any conclusions can be drawn about the clinical utility of PRP for neurodegenerative conditions or cognitive enhancement in healthy populations.

The growth factor cocktail in colostrum (EGF, TGF-beta, IGF-1, PDGF, VEGF) provides a combination of factors that may support tissue repair processes. EGF accelerates re-epithelialization by stimulating keratinocyte migration and proliferation. TGF-beta promotes extracellular matrix deposition and angiogenesis. IGF-1 stimulates fibroblast proliferation and collagen synthesis, while VEGF promotes neovascularization of healing tissue.

Preclinical studies have demonstrated accelerated wound closure in experimental models when colostrum components are applied. The combination of multiple growth factors may be more effective than single-growth-factor therapies, as it better approximates the natural coordination of tissue repair processes. However, clinical evidence for wound healing applications in humans remains limited.

Colostrum provides antimicrobial defense through the synergistic action of immunoglobulins, lactoferrin, lysozyme, lactoperoxidase, and antimicrobial peptides [7]. This multi-component approach may reduce the likelihood of resistance development and provides coverage against bacteria, viruses, fungi, and protozoa.

Immunoglobulins neutralize pathogens through direct binding. Lactoferrin exerts antimicrobial effects through iron sequestration, direct membrane disruption via lactoferricin, and biofilm inhibition. Lysozyme hydrolyzes bacterial cell walls. The lactoperoxidase system produces hypothiocyanite, which is toxic to various microorganisms. Together, these components form a comprehensive antimicrobial defense system [6].

Lactoferrin has demonstrated antiviral activity against several viruses in experimental systems, including rotavirus, HIV, herpes simplex virus, and influenza virus. The mechanisms include binding to viral particles and host cell receptors, interfering with viral attachment and entry. Immunoglobulins in colostrum also contribute to viral neutralization [3].

Bovine colostrum has been consumed for centuries and has a generally favorable safety profile. Long-term feeding studies in rats (90 days at 10 percent colostrum in the diet) showed no abnormalities in physiological parameters or tissue histology, as reviewed by Yalçıntaş et al. (2024) [2]. Human studies have consistently reported minimal adverse effects, with the most common complaints being mild gastrointestinal symptoms that typically resolve with continued use.

Certain populations should exercise caution when using colostrum supplements. Individuals with dairy allergies may react to casein and beta-lactoglobulin present in colostrum. Those with lactose intolerance may experience symptoms due to the lactose content. The presence of trace amounts of hormones in colostrum has raised questions about potential effects in hormone-sensitive conditions, though the clinical significance of these trace levels is uncertain [2]. Pregnant and lactating women should consult healthcare providers before use, as safety data in these populations are limited.

The bioactive component content of colostrum products varies considerably depending on collection time, processing method, and quality control measures [1]. Colostrum collected within 24 hours of calving (first milking preferred) contains the highest concentrations of immunoglobulins and bioactive components. Processing methods such as pasteurization and drying can affect the stability of heat-sensitive components. Consumers should seek products that specify IgG content, are processed using low-heat methods, and are tested for microbial contamination.

While preclinical and early clinical studies have generated interest in the potential health benefits of bovine colostrum, significant gaps in the evidence remain. Many clinical trials have been small, short in duration, or methodologically limited. The optimal dosage, timing, and duration of supplementation have not been established for most applications. Furthermore, the bioavailability and stability of colostral bioactive components after oral administration in humans require further investigation [5].

Most published clinical trials have involved fewer than 100 participants and have been of short duration (typically 4 to 12 weeks). There is a lack of large-scale, long-term randomized controlled trials that could provide definitive evidence for the efficacy of colostrum supplementation in specific clinical conditions. Additionally, standardization of colostrum products remains a challenge, as the bioactive component content varies considerably depending on collection time, processing method, and quality control measures [1]. Future research should focus on establishing standardized products with defined bioactive component profiles, conducting larger clinical trials with appropriate controls, and investigating the mechanisms underlying observed effects. Particular attention should be paid to determining the bioavailability of colostral bioactive components after oral administration, as many of these components, including immunoglobulins and growth factors, may be partially or fully degraded by digestive enzymes. Advances in encapsulation and delivery technologies may help overcome these limitations. Additionally, research into the potential synergistic effects of colostrum components, both with each other and with other dietary or therapeutic interventions, may reveal opportunities for enhanced efficacy. The identification of responsive subpopulations, based on genetic, microbiome, or immune status, may help personalize colostrum supplementation strategies and improve outcomes.

Bovine colostrum contains a diverse array of bioactive components that have been investigated for various potential health-related properties. The evidence base varies considerably across applications. Areas with relatively more supportive evidence include effects on mucosal immune function, gastrointestinal protection (particularly against infectious diarrhea and NSAID-induced injury), attenuation of exercise-induced gut permeability, and exercise-related recovery. Areas with preliminary or limited evidence include neuroprotection, wound healing, and allergy prevention.

In evaluating the potential benefits of colostrum supplementation, it is important to maintain a distinction between the established nutritional and immunological roles of colostrum in neonatal mammals and the proposed benefits of bovine colostrum supplementation in human adults and children. While the biological activities of colostral components are documented in experimental systems, the translation of these activities into clinically meaningful health outcomes requires further investigation through larger, well-controlled clinical trials.

Significant gaps in the evidence remain, including optimal dosage, timing, and duration of supplementation for specific applications; bioavailability and stability of bioactive components after oral administration; and long-term safety data. As research continues, additional applications may emerge, but current evidence supports a cautious and evidence-based approach to colostrum supplementation.

The content and information published on this website are intended exclusively for business partners (including corporate clients, suppliers, and distributors). No section of this website is presented to individual end consumers. Entities not formally engaged in a commercial relationship with Kangping Bio are not entitled to access, quote, or rely upon the professional business information herein. Our products are not medicines and are not intended to diagnose, treat, prevent, or cure any disease. They must not be used as a substitute for pharmaceuticals or medical devices for any disease-related purpose, and must not be promoted, procured, or used as medical products. The research data cited herein are sourced from published academic papers and do not represent the position or product statements of Heilongjiang Kangping Bioengineering Co., Ltd. By continuing to use this website and browse its content, you acknowledge and accept our Terms of Use and Privacy Policy.